Cereblon expression in multiple myeloma: not ready for prime time - response to Lodé et al

Affiliations

Comment

Niklas Zojer et al. Br J Haematol. 2013 Oct.

. 2013 Oct;163(2):285-6.

doi: 10.1111/bjh.12477. Epub 2013 Jul 19.

¹ Department of Internal Medicine I, Centre for Oncology and Haematology, Wilhelminenspital, Vienna, Austria.

No abstract available

Keywords: bone-marrow microenvironment; cereblon; immunomodulatory drugs; therapy resistance.

Comment on

High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.
Heintel D, Rocci A, Ludwig H, Bolomsky A, Caltagirone S, Schreder M, Pfeifer S, Gisslinger H, Zojer N, Jäger U, Palumbo A. Heintel D, et al. Br J Haematol. 2013 Jun;161(5):695-700. doi: 10.1111/bjh.12338. Epub 2013 Apr 9. Br J Haematol. 2013. PMID: 23565715
Cereblon expression in multiple myeloma: not ready for prime time.
Lodé L, Amiot M, Maiga S, Touzeau C, Menard A, Magrangeas F, Minvielle S, Pellat-Deceunynck C, Bene MC, Moreau P. Lodé L, et al. Br J Haematol. 2013 Oct;163(2):282-4. doi: 10.1111/bjh.12478. Epub 2013 Jul 17. Br J Haematol. 2013. PMID: 23862718 No abstract available.